Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma.
about
Human papillomavirus DNA in plasma of patients with cervical cancerUnderstanding the interplay between host immunity and Epstein-Barr virus in NPC patientsDistribution of epstein-barr virus antigenic sites on the carboxyl terminal end of ribonucleotide reductase against nasopharyngeal carcinoma serum antibodies using an immunoabsorption method.Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for fieNoise cancellation: viral fine tuning of the cellular environment for its own genome replication.Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator ZtaEpstein-Barr virus Zta upregulates matrix metalloproteinases 3 and 9 that synergistically promote cell invasion in vitro.Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicityEvaluation of an immunofiltration assay that detects immunoglobulin M antibodies against the ZEBRA protein for the diagnosis of Epstein-Barr virus infectious mononucleosis in immunocompetent patientsMethods and matrices: approaches to identifying miRNAs for nasopharyngeal carcinoma.The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal.Serum Zta antibody of Epstein-Barr virus exerts potential function in the diagnosis of nasopharyngeal cancer.Pin1 interacts with the Epstein-Barr virus DNA polymerase catalytic subunit and regulates viral DNA replication.Development of a time-resolved fluorescence immunoassay for Epstein-Barr virus Zta IgA antibodies in human serum.Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry.The BFRF1 gene of Epstein-Barr virus encodes a novel protein.Transcriptional repression by sumoylation of Epstein-Barr virus BZLF1 protein correlates with association of histone deacetylase.Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1-encoded transactivator protein among human immunodeficiency virus-infected patients.Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism.Antibodies to Epstein-Barr virus thymidine kinase: a characteristic marker for the serological detection of nasopharyngeal carcinoma.The ecology and pathology of Epstein-Barr virus.SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function.ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus.Evidence of lytic infection of Epstein-Barr virus (EBV) in EBV-positive gastric carcinoma.Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease.Antibody against the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2, in patients with nasopharyngeal carcinoma.
P2860
Q24798417-882623FA-061E-4CDC-B127-775E45D8BC29Q26823898-FCED01EF-C7E8-4F11-AA36-9F50B06E5A8AQ30780410-BFC44952-50EC-461F-989F-E5A45C05FD04Q33239049-E1AF3F8A-3406-41D9-A56B-917FB2523AB8Q33780955-E2F5AEF6-58EA-43DB-9F50-E66296425A82Q33809585-3DFB5CBF-77B2-4023-801B-35EC9C1B753BQ34586675-1BA4BA3D-6C33-471D-B98A-51AA09207359Q35783467-06E129A0-4F12-43F3-AE9C-47A912A38A42Q37213859-C58E9ACB-C391-45D1-BE22-1D60E34D25D9Q37493553-B659FC69-42FF-4EF8-AA71-F6C30240D05AQ37549340-122AAE1E-4C5C-460D-8D77-1614CB36ABB4Q38398399-3DFEF39A-304E-4496-99FE-D90938FA3083Q39230419-76A7B629-524A-4DF2-8663-79527467AA1FQ39396128-C18EC405-98EE-4E5D-ADEA-756231A1010AQ39507024-F12FD4BB-31AE-4C9E-8BA8-DE85CB56B5DFQ39590218-E4D0008A-EDDC-455F-B1BA-8A9DAD61D95BQ39697772-D73FA785-9D5A-4F36-9426-91E41E3DD3A6Q39810535-586A24A9-A1FE-4281-9495-FCA7862C0087Q39914140-BDD6C2F2-BC7F-4779-8E19-E6CCDE8C1C25Q40818466-DCA4CBBE-1E03-4A55-8FC8-4D24A2A49715Q41036904-291C2CD6-DA0B-447A-83D3-BDA9F0A49085Q41983297-BF190904-C27D-4929-9873-71D428971E92Q43875479-43E6A0EB-CEB7-4876-B301-EE82A87BC486Q45734089-DE4CFA3A-40CA-4A56-BD8F-59ACB5BF510BQ45744229-FDF7B398-CC71-420B-A6E8-1B1787409C65Q45750564-E561766F-5E28-4417-82F9-40C7BB952DF1Q45753261-DFDA0BE1-0C85-411D-B32C-CB5C8D879B1C
P2860
Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Detection of anti-Epstein-Barr ...... with nasopharyngeal carcinoma.
@en
type
label
Detection of anti-Epstein-Barr ...... with nasopharyngeal carcinoma.
@en
prefLabel
Detection of anti-Epstein-Barr ...... with nasopharyngeal carcinoma.
@en
P2093
P356
P1476
Detection of anti-Epstein-Barr ...... with nasopharyngeal carcinoma.
@en
P2093
P304
P356
10.1002/IJC.2910480503
P577
1991-07-01T00:00:00Z